SNORA52: A Potential Drug Target and Biomarker for Cancer (G619565)

Target Name: SNORA52

NCBI ID: G619565

SNORA52

Other Name(s): ACA52 | small nucleolar RNA, H/ACA box 52 | Small nucleolar RNA, H/ACA box 52

SNORA52: A Potential Drug Target and Biomarker for Cancer

SNORA52 (ACA52) is a drug target and a potential biomarker for the treatment of various diseases, including cancer. SNORA52 is a small non-coding RNA molecule that plays a critical role in cell signaling pathways, specifically in the regulation of cell adhesion and migration.

The discovery of SNORA52 as a potential drug target and biomarker has significant implications for the development of new treatments for various diseases. The research on SNORA52 has been primarily focused on its role in cancer, where it has been shown to be involved in the regulation of cell adhesion, migration, and angiogenesis.

Studies have shown that SNORA52 is highly expressed in various types of cancer, including breast, ovarian, and colorectal cancer. It has also been found to be associated with cancer cell survival and the development of resistance to chemotherapy.

In addition to its role in cancer, SNORA52 has also been shown to be involved in the regulation of cell signaling pathways that are important for overall cellular health and survival. Studies have shown that SNORA52 plays a critical role in the regulation of T cell development and function, and that it is involved in the regulation of inflammation and cellular stress.

The potential clinical applications of SNORA52 as a drug target and biomarker are vast. Given its involvement in cell signaling pathways and its potential role in the regulation of cancer growth and treatment resistance, SNORA52 has the potential to be used as a target for small molecule inhibitors, monoclonal antibodies, or other therapeutic approaches.

In addition to its potential as a drug target, SNORA52 has also been shown to be a potential biomarker for cancer. Its expression has been found to be associated with the development of various types of cancer, including breast, ovarian, and colorectal cancer. Additionally, studies have shown that SNORA52 has been able to be used as a biomarker for monitoring the effectiveness of cancer treatments, including cancer vaccines and targeted therapies.

Overall, the discovery of SNORA52 as a potential drug target and biomarker for cancer has significant implications for the development of new treatments for this disease. Further research is needed to fully understand its role in cell signaling pathways and its potential as a therapeutic approach.

Protein Name: Small Nucleolar RNA, H/ACA Box 52

The "SNORA52 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORA52 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets